Publicaciones en colaboración con investigadores/as de Universidad Autónoma de Madrid (51)

2022

  1. Polyfunctionalized α-Phenyl-tert-butyl(benzyl)nitrones: Multifunctional Antioxidants for Stroke Treatment

    Antioxidants, Vol. 11, Núm. 9

  2. Synthesis and Pharmacological Evaluation of New N-Sulfonylureas as NLRP3 Inflammasome Inhibitors: Identification of a Hit Compound to Treat Gout

    Journal of Medicinal Chemistry, Vol. 65, Núm. 8, pp. 6250-6260

2021

  1. (±)- BIGI-3h: Pentatarget-Directed Ligand combining Cholinesterase, Monoamine Oxidase, and Glycogen Synthase Kinase 3β Inhibition with Calcium Channel Antagonism and Antiaggregating Properties for Alzheimer's Disease

    ACS Chemical Neuroscience, Vol. 12, Núm. 8, pp. 1328-1342

2020

  1. In Vitro and in Silico ADME-Tox Profiling and Safety Significance of Multifunctional Monoamine Oxidase Inhibitors Targeting Neurodegenerative Diseases

    ACS Chemical Neuroscience, Vol. 11, Núm. 22, pp. 3793-3801

2019

  1. Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer’s disease therapy

    Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 34, Núm. 1, pp. 479-489

  2. New Dual Small Molecules for Alzheimer's Disease Therapy Combining Histamine H3 Receptor (H3R) Antagonism and Calcium Channels Blockade with Additional Cholinesterase Inhibition

    Journal of Medicinal Chemistry, Vol. 62, Núm. 24, pp. 11416-11422

  3. Quinoxalinetacrine QT78, a cholinesterase inhibitor as a potential ligand for Alzheimer’s disease therapy

    Molecules, Vol. 24, Núm. 8

  4. Tacrines for Alzheimer's disease therapy. III. The PyridoTacrines

    European Journal of Medicinal Chemistry, Vol. 166, pp. 381-389

2017

  1. Ischemic brain injury: New insights on the protective role of melatonin

    Free Radical Biology and Medicine, Vol. 104, pp. 32-53

  2. Melatonin as a versatile molecule to design novel multitarget hybrids against neurodegeneration

    Future Medicinal Chemistry, Vol. 9, Núm. 8, pp. 765-780

2016

  1. Melatonin protects against oxygen and glucose deprivation by decreasing extracellular glutamate and Nox-derived ROS in rat hippocampal slices

    NeuroToxicology, Vol. 57, pp. 61-68

  2. N-Benzylpiperidine Derivatives as α7 Nicotinic Receptor Antagonists

    ACS Chemical Neuroscience, Vol. 7, Núm. 8, pp. 1157-1165

  3. The Antioxidant Additive Approach for Alzheimer's Disease Therapy: New Ferulic (Lipoic) Acid Plus Melatonin Modified Tacrines as Cholinesterases Inhibitors, Direct Antioxidants, and Nuclear Factor (Erythroid-Derived 2)-Like 2 Activators

    Journal of Medicinal Chemistry, Vol. 59, Núm. 21, pp. 9967-9973

2015

  1. Development of HuperTacrines as non-toxic, cholinesterase inhibitors for the potential treatment of Alzheimer’s disease

    Mini-Reviews in Medicinal Chemistry, Vol. 15, Núm. 8, pp. 648-658

  2. Novel tacrine-grafted ugi adducts as multipotent anti-alzheimer drugs: A synthetic renewal in tacrine-ferulic acid hybrids

    ChemMedChem, Vol. 10, Núm. 3, pp. 523-539

2014

  1. Isoxazolotacrines as non-toxic and selective butyrylcholinesterase inhibitors for Alzheimer's disease

    Future Medicinal Chemistry, Vol. 6, Núm. 17, pp. 1883-1891

2013

  1. Dihydrocyclam dimaleate [H2(cyclam)(maleate)2]

    Acta Crystallographica Section E: Structure Reports Online, Vol. 69, Núm. 10

  2. Enantioselective neuroprotective effects of tacripyrine ITH122 against oxygen and glucose deprivation in rat hippocampal slices

    CNS Neuroscience and Therapeutics

  3. PP2A ligand ITH12246 protects against memory impairment and focal cerebral ischemia in mice

    ACS Chemical Neuroscience, Vol. 4, Núm. 9, pp. 1267-1277

  4. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease

    Medicinal Research Reviews, Vol. 33, Núm. 1, pp. 139-189